The Link between Caveolae, Metabolic Syndrome, and Cateractogenesis: A Mechanistic Hypothesis

Cataract, the leading cause of blindness worldwide, results from progressive lens opacification driven by oxidative stress, protein aggregation, and metabolic dysregulation. While aging remains the primary risk factor, systemic metabolic disorders, particularly metabolic syndrome (MetS), are increasingly recognized as major contributors to cataractogenesis. MetS, a constellation of central obesity, hypertension, hyperglycemia, and dyslipidemia, exacerbates oxidative stress, inflammation, and metabolic imbalance, thereby accelerating lens degeneration.A novel and largely unexplored mechanism underlying MetS-induced cataract involves dysfunction of caveolae, cholesterol-rich plasma membrane microdomains composed of caveolin proteins. Caveolae are highly expressed in lens epithelial cells and play essential roles in nutrient transport, insulin signaling, lipid trafficking, and oxidative stress regulation. Disruption of caveolae integrity in MetS impairs insulin receptor, PI3K/Akt signaling, reduces glucose uptake, and compromises lens cell survival. In parallel, loss of caveolae function diminishes antioxidant buffering capacity and alters lipid homeostasis, promoting lipid peroxidation, membrane instability, and crystallin aggregation. These processes collectively establish a pro-cataractogenic microenvironment, linking systemic metabolic dysfunction to lens pathology through a unique membrane-based pathway.Clinically, cataracts in patients with MetS often present with similar visual symptoms to age-related forms but demonstrate earlier onset and faster progression, especially under poorly controlled metabolic conditions. Recognition of caveolae-dependent pathways as mediators of this process not only provides a new perspective on cataract pathophysiology but also opens the possibility of integrated co-treatment strategies. Therapeutic strategies that restore caveolae function through molecular interventions, antioxidant therapy, and systemic metabolic control may offer a unified approach to slowing both MetS progression and cataract development. Elucidating this unexplored mechanism holds promise for the design of innovative, dual-targeted therapies for patients with coexisting metabolic and ocular disease.